COVID-19 Reactivates Dormant Viruses, Study Finds

SARS-CoV-2 infection, the virus responsible for COVID-19, has been found to reactivate a range of dormant viruses residing within the human body, according to a study published online on August 5, 2026, in the journal Nature. This reactivation phenomenon appears to be particularly pronounced with anelloviruses, a group of typically harmless viruses that infect humans. The research suggests a potential link between the reactivation of these anelloviruses and the development of long COVID, a condition characterized by persistent symptoms following an initial SARS-CoV-2 infection.

The study, which utilized advanced molecular techniques to analyze viral activity in individuals who had contracted COVID-19, identified significant increases in the replication of previously dormant viral genomes. While the full implications of this widespread viral reactivation are still under investigation, the researchers highlight that the immune system's response to SARS-CoV-2 may inadvertently disrupt the delicate balance that keeps other viruses in a latent state. This disruption could allow these latent viruses to re-emerge and potentially contribute to the complex and varied symptoms experienced by individuals with long COVID.

Anelloviruses, a family of single-stranded DNA viruses, are ubiquitous in the human population, with seroprevalence rates often exceeding 90%. They are generally considered non-pathogenic, meaning they do not cause disease in healthy individuals. However, their persistence in the body and their ability to replicate suggest a complex interaction with the host's immune system. The findings in Nature indicate that the immune dysregulation caused by SARS-CoV-2 infection might compromise the host's ability to keep anelloviruses suppressed, leading to their reactivation.

This discovery opens new avenues for understanding the pathogenesis of long COVID. While fatigue, respiratory issues, and neurological symptoms are commonly reported, the role of reactivated endogenous viruses has been a subject of ongoing research. The study's authors propose that the increased viral load from reactivated anelloviruses could trigger or exacerbate inflammatory responses, contributing to the chronic symptoms associated with long COVID. Further research is planned to explore whether targeting these reactivated viruses could offer therapeutic benefits for patients suffering from long COVID. The study's findings, published with the DOI 10.1038/d41586-026-02443-2, underscore the multifaceted impact of SARS-CoV-2 infection on the human virome and immune system.